newstart_MO said:The mechanism is more central than most summaries suggest.
That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.
newstart_MO said:The mechanism is more central than most summaries suggest.
That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.
Adding the clinical framing, because it changes how the question reads.
Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.
Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.
DeniseRN_TPA said:I want to bring up the cardiovascular angle on cardiovascular risk.
CRP reduction on cardiovascular risk — this is the lab result that excites me most:
Baseline hsCRP: 8.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 1.5 mg/L (moderate risk)
Month 12 hsCRP: 0.8 mg/L (low risk)
This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 15% to 4%. My cardiologist is genuinely impressed.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.RenalNash said:SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:
The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.
Moderator note: the sourcing question belongs in the vendor section and has been split out. Tagging this one for the weekly digest.